Health Care Stocks On The Rise With Help From 5 Stocks

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 22 points (-0.2%) at 14,429 as of Tuesday, March 19, 2013, 12:45 PM ET. The NYSE advances/declines ratio sits at 1,094 issues advancing vs. 1,811 declining with 142 unchanged.

The Health Care sector currently sits down 0.5% versus the S&P 500, which is down 0.4%. Top gainers within the sector include HCA Holdings ( HCA), up 1.7%, Novartis ( NVS), up 1.2% and Shire ( SHPG), up 1.1%. On the negative front, top decliners within the sector include Intuitive Surgical ( ISRG), down 1.9%, Alexion Pharmaceuticals ( ALXN), down 1.2%, Gilead ( GILD), down 1.3%, Celgene Corporation ( CELG), down 0.8% and Teva Pharmaceutical Industries ( TEVA), down 0.6%.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector higher today:

5. Valeant Pharmaceuticals International ( VRX) is one of the companies pushing the Health Care sector higher today. As of noon trading, Valeant Pharmaceuticals International is up $1.00 (1.4%) to $71.54 on heavy volume Thus far, 1.0 million shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $70.57-$72.04 after having opened the day at $70.67 as compared to the previous trading day's close of $70.54.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $21.4 billion and is part of the drugs industry. Shares are up 18.0% year to date as of the close of trading on Monday. Currently there are 12 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Valeant Pharmaceuticals International Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

4. As of noon trading, GlaxoSmithKline ( GSK) is up $0.52 (1.2%) to $45.64 on heavy volume Thus far, 1.7 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $45.41-$45.87 after having opened the day at $45.55 as compared to the previous trading day's close of $45.12.

GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $122.3 billion and is part of the drugs industry. The company has a P/E ratio of 13.6, below the S&P 500 P/E ratio of 17.7. Shares are up 3.8% year to date as of the close of trading on Monday. Currently there are 2 analysts that rate GlaxoSmithKline a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full GlaxoSmithKline Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

3. As of noon trading, Regeneron Pharmaceuticals ( REGN) is up $5.97 (3.5%) to $176.08 on average volume Thus far, 406,121 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 811,900 shares. The stock has ranged in price between $171.20-$177.99 after having opened the day at $171.20 as compared to the previous trading day's close of $170.11.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $16.4 billion and is part of the drugs industry. The company has a P/E ratio of 25.5, above the S&P 500 P/E ratio of 17.7. Shares are down 0.6% year to date as of the close of trading on Monday. Currently there are 7 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Regeneron Pharmaceuticals Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

2. As of noon trading, Bristol-Myers Squibb Company ( BMY) is up $0.20 (0.5%) to $39.08 on light volume Thus far, 3.3 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 9.3 million shares. The stock has ranged in price between $38.85-$39.25 after having opened the day at $38.94 as compared to the previous trading day's close of $38.88.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $63.8 billion and is part of the drugs industry. The company has a P/E ratio of 33.6, above the S&P 500 P/E ratio of 17.7. Shares are up 19.3% year to date as of the close of trading on Monday. Currently there are 7 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 13 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, solid stock price performance, growth in earnings per share, largely solid financial position with reasonable debt levels by most measures and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Bristol-Myers Squibb Company Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

1. As of noon trading, Amgen ( AMGN) is up $1.15 (1.3%) to $91.54 on light volume Thus far, 1.5 million shares of Amgen exchanged hands as compared to its average daily volume of 5.6 million shares. The stock has ranged in price between $90.54-$92.05 after having opened the day at $90.68 as compared to the previous trading day's close of $90.39.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $68.7 billion and is part of the drugs industry. The company has a P/E ratio of 16.6, below the S&P 500 P/E ratio of 17.7. Shares are up 4.9% year to date as of the close of trading on Monday. Currently there are 13 analysts that rate Amgen a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Amgen Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null